Peptides, those elegant short chains of amino acids linked by sturdy bonds, form the backbone of life's intricate machinery. Their story begins in the early 19th century, a time when chemistry was unraveling the mysteries of organic matter. In 1820, French chemist Henri Braconnot boiled gelatin with sulfuric acid and isolated glycine, the simplest amino acid, marking the first step toward understanding proteins' components. Over the next decades, scientists like William Prout and Justus von Liebig cataloged more amino acids—leucine in 1820, tyrosine in 1846, and tryptophan in 1901—piecing together the puzzle of these nitrogen-rich building blocks. But it was German chemist Emil Fischer who truly ignited the peptide revolution. In the late 1890s, Fischer proposed that amino acids were connected via what he called "peptide bonds," a term he coined from the Greek "peptos," meaning digested. By 1901, he synthesized the first dipeptide, glycylglycine (Gly-Gly), using innovative protection strategies to link amino acids without unwanted side reactions. This feat not only earned Fischer the 1902 Nobel Prize in Chemistry but also laid the groundwork for peptide science, transforming abstract concepts into tangible molecules. By the turn of the century, over 20 amino acids were known, setting the stage for peptides' leap from lab curiosities to biological powerhouses.
The Insulin Breakthrough: A Lifesaving Peptide Emerges
The 1920s heralded peptides' entry into medicine with one of history's most dramatic discoveries: insulin. In 1921, Canadian researchers Frederick Banting and Charles Best, working at the University of Toronto, extracted insulin from dog pancreases, demonstrating its ability to lower blood sugar in diabetic animals. Their work, refined with biochemist James Collip, led to the first human trials in 1922, where a 14-year-old boy named Leonard Thompson saw his blood glucose plummet from lethal levels. By 1923, Eli Lilly commercialized insulin, saving millions from the once-fatal scourge of type 1 diabetes. This peptide hormone, composed of 51 amino acids in two chains linked by disulfide bridges, underscored peptides' therapeutic potential. Yet, early insulin was sourced from animal pancreases—up to 10,000 pigs yielded just a few grams—highlighting supply challenges. In 1935, German chemist Adolf Butenandt isolated oxytocin and vasopressin from pituitary glands, revealing peptides' roles in labor induction and blood pressure regulation. These isolations, yielding mere milligrams from tons of tissue, emphasized the need for better synthesis methods. By the 1940s, peptides were recognized as hormones, neurotransmitters, and antibiotics, with natural ones like gramicidin (isolated in 1939) combating bacterial infections during World War II.
Decoding the Code: Sequencing and Synthesis Milestones
The 1950s brought clarity to peptide structures through sequencing breakthroughs. British biochemist Frederick Sanger, using innovative chromatography and labeling techniques, fully sequenced insulin in 1951, revealing its A-chain (21 amino acids) and B-chain (30 amino acids). This achievement, the first for any protein, earned Sanger the 1958 Nobel Prize and proved peptides were precise sequences, not random aggregates. In 1953, American chemist Vincent du Vigneaud synthesized oxytocin, a nine-amino-acid peptide, confirming its structure and earning him the 1955 Nobel Prize. These feats demystified peptides, enabling targeted modifications. However, manual synthesis was laborious until 1963, when American chemist Robert Bruce Merrifield invented solid-phase peptide synthesis (SPPS). By anchoring the first amino acid to an insoluble resin bead and adding others stepwise, Merrifield automated the process, slashing synthesis time from years to days. His method produced ribonuclease A in 1969, a 124-amino-acid enzyme, and earned the 1984 Nobel Prize. SPPS revolutionized the field, with over 80% of synthetic peptides today relying on it, facilitating production scales from milligrams to kilograms.
Peptides Storm the Clinic: From Hormones to Pharmaceuticals
The 1970s and 1980s saw peptides transition from research tools to blockbuster drugs. Gonadotropin-releasing hormone (GnRH), a 10-amino-acid peptide discovered in 1971, became the first synthetic peptide therapeutic in the mid-1970s, treating infertility and hormone-dependent cancers like prostate cancer. Analogs like leuprolide, approved in 1985, generated billions in sales by modulating hormone levels. In 1978, Genentech's David Goeddel produced recombinant human insulin using E. coli bacteria, leading to FDA approval in 1982 as Humulin—the first biotech drug. This shift from animal sources to microbial factories addressed allergies and supply issues, with recombinant insulin now dominating a market worth over $20 billion annually. By the 1980s, peptide antibiotics like polymyxin (discovered in 1947 but refined) fought resistant bacteria. In 1986, GLP-1 was identified, spawning diabetes drugs like exenatide (approved 2005), which mimics incretin hormones to regulate blood sugar. By 1990, over 20 peptide drugs were approved, with the field exploding thanks to mass spectrometry and proteomics, identifying thousands of bioactive peptides in human tissues.
Biotech Renaissance: Engineering Peptides for the Modern Era
The 1990s and 2000s propelled peptides into biotechnology's forefront. Phage display technology, pioneered by George Smith in 1985 and refined in the 1990s, allowed screening billions of peptide variants for binding affinity, accelerating drug discovery. This led to enfuvirtide (Fuzeon), a 36-amino-acid HIV fusion inhibitor approved in 2003, blocking viral entry and saving lives in antiretroviral therapy. Ziconotide, a 25-amino-acid cone snail venom peptide, gained FDA approval in 2004 for chronic pain, binding calcium channels with potency 1,000 times that of morphine. Cosmetics embraced peptides too; in 1993, the pentapeptide KTTKS (Matrixyl) was patented for stimulating collagen, reducing wrinkles in skincare products worth $5 billion yearly. By 2010, over 60 peptide drugs were marketed, with innovations like peptide-drug conjugates (e.g., lutetium 177 dotatate, approved 2018 for neuroendocrine tumors) delivering targeted radiation. Nanotechnology enhanced delivery, encapsulating peptides in liposomes to evade degradation, while cyclization and non-natural amino acids boosted stability—extending half-lives from minutes to days.
Peptides Today: Innovations Reshaping Medicine and Beyond
In the 2020s, peptides dominate biotech, with over 80 approved drugs worldwide and 170 in clinical trials. Sales surpassed $70 billion in 2019, driven by GLP-1 agonists like semaglutide (Ozempic, $14 billion in 2023 sales) for diabetes and obesity. Oral peptides emerged with Rybelsus (2019), using absorption enhancers to bypass digestion. In oncology, peptides like carfilzomib (2012) inhibit proteasomes in multiple myeloma, while vaccine peptides target cancer antigens. Antiviral peptides, such as myrcludex B for hepatitis, and antimicrobial ones combat superbugs, with 2024 seeing AI-driven designs predicting structures. Cosmetics leverage peptides for whitening (e.g., PKEK tetrapeptide) and repair, with the market hitting $10 billion. Biotech extends to materials science, where self-assembling peptides form hydrogels for tissue engineering, regenerating organs in trials.
The Peptide Horizon: Endless Possibilities Ahead
As we stand in 2025, peptides' journey from Fischer's lab to global biotech giants inspires awe. With CRISPR editing peptides and quantum computing optimizing designs, the future promises personalized therapies, conquering diseases like Alzheimer's and cancer. Over 500 peptides in preclinical stages hint at a $100 billion market by 2030. This molecular odyssey, blending history's ingenuity with tomorrow's tech, affirms peptides as nature's versatile warriors, forever transforming human health.
Reference:
1. Bentley, G., Perfito, N., Ukena, K., Tsutsui, K., & Wingfield, J. (2003). Gonadotropin‐inhibitory peptide in song sparrows (melospiza melodia) in different reproductive conditions, and in house sparrows (passer domesticus) relative to chicken‐gonadotropin‐releasing hormone. Journal of Neuroendocrinology, 15(8), 794-802. https://doi.org/10.1046/j.1365-2826.2003.01062.x
2. Bogerd, J., Zandbergen, T., Andersson, E., & Goos, H. (1994). Isolation, characterization and expression of cdnas encoding the catfish‐type and chicken‐ii‐type gonadotropin‐releasing‐hormone precursors in the african catfish. European Journal of Biochemistry, 222(2), 541-549. https://doi.org/10.1111/j.1432-1033.1994.tb18896.x
Craig, A., DeBoard, R., Kirby, D., Jiang, G., Koerber, S., & Rivier, J. (2001). Characterization of betidamino acid-containing somatostatin and gonadotropin-releasing hormone analogs with electrospray mass spectrometry and tandem mass spectrometry. European Journal of Mass Spectrometry, 7(3), 259-266. https://doi.org/10.1255/ejms.436